Anxiety and Panic Disorder Treatment in Adolescents

Initial Treatment Approach

The American Academy of Child and Adolescent Psychiatry recommends starting combination therapy with cognitive-behavioral therapy (CBT) plus an SSRI (specifically sertraline) immediately for adolescents with functionally impairing anxiety and panic disorder, as this approach demonstrates superior efficacy compared to either treatment alone 1.
Combination treatment with CBT plus sertraline is the gold standard for adolescents aged 6-18 years with functionally impairing anxiety and panic disorder, showing moderate to high strength of evidence for improved anxiety symptoms, global function, treatment response, and disorder remission compared to monotherapy 2, 3, 1.

The treatment guidelines suggest starting sertraline at 25 mg daily for 3-7 days, then increasing to 50 mg daily by week 1-2, with a target therapeutic dose of 50-175 mg daily 4.
Alternative SSRI options if sertraline is not tolerated include escitalopram, starting at 5-10 mg daily, and fluoxetine, starting at 5-10 mg daily and increasing by 5-10 mg increments every 1-2 weeks 5, 4.
Statistically significant improvement may begin by week 2, with clinically significant improvement expected by week 6, and maximal therapeutic benefit achieved by week 12 or later 5, 2.

The American Academy of Child and Adolescent Psychiatry recommends referring immediately for individual CBT specifically designed for anxiety and panic disorder, targeting 12-20 structured sessions 2, 6, 1.
Essential CBT elements must include education about anxiety and panic physiology, cognitive restructuring, graduated exposure to social and performance situations, relaxation techniques, and interoceptive exposure for panic-related physical sensations 2, 1.

Coordinate immediately with school to implement accommodations for panic attacks, including a safe space and ability to leave class briefly during panic episodes 1.
Monitor weekly for suicidal ideation and behavior, especially in the first weeks after starting or increasing SSRI dose, as adolescents have increased risk with a pooled risk difference of 0.7% vs placebo (number needed to harm = 143) 5, 1, 4.
Assess treatment response using standardized anxiety rating scales (e.g., HAM-A) to supplement clinical interview 2, 5.

Continue medication for a minimum of 12-24 months after symptom remission, then taper gradually over 2-4 weeks when discontinuing to avoid withdrawal symptoms 5, 4.
Do not use benzodiazepines as first-line treatment due to risks of dependence, cognitive impairment, and lack of evidence for long-term efficacy in adolescents 1.
Do not use beta-blockers (propranolol, atenolol) for panic disorder treatment, as they do not treat the underlying condition and may provide only symptom relief for palpitations and tremors 4, 5.